Robert Glassman Sells 8,667 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Robert Glassman sold 8,667 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $38.27, for a total transaction of $331,686.09. Following the sale, the director directly owned 10,500 shares of the company’s stock, valued at $401,835. This represents a 45.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Robert Glassman also recently made the following trade(s):

• On Wednesday, September 9th, Robert Glassman sold 8,000 shares of Pharvaris stock. The stock was sold at an average price of $37.55, for a total transaction of $300,400.00.

Pharvaris Trading Down 4.3%

Shares of NASDAQ PHVS opened at $36.37 on Friday. The firm has a market cap of $2.38 billion, a PE ratio of -11.92 and a beta of -2.33. Pharvaris N.V. has a 1-year low of $20.65 and a 1-year high of $43.25. The company has a fifty day moving average price of $35.37 and a 200 day moving average price of $31.73.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Equities research analysts forecast that Pharvaris N.V. will post -3.12 EPS for the current year.

Wall Street Analyst Weigh In

PHVS has been the topic of several research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $65.00 target price on shares of Pharvaris in a research note on Monday. Wells Fargo & Company lifted their price objective on shares of Pharvaris from $55.00 to $65.00 and gave the company an “overweight” rating in a report on Wednesday, September 9th. UBS Group set a $79.00 price objective on shares of Pharvaris in a research report on Wednesday, September 9th. Citizens Jmp increased their target price on shares of Pharvaris from $75.00 to $79.00 and gave the stock a “market outperform” rating in a report on Wednesday, September 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a research report on Tuesday, September 8th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Pharvaris has a consensus rating of “Moderate Buy” and a consensus price target of $59.87.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PHVS. venBio Partners LLC acquired a new position in shares of Pharvaris during the 2nd quarter worth approximately $160,569,809. Wellington Management Group LLP boosted its holdings in shares of Pharvaris by 12.9% in the 2nd quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after buying an additional 274,034 shares during the last quarter. Commodore Capital LP grew its stake in shares of Pharvaris by 1.6% in the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock valued at $54,211,000 after buying an additional 29,525 shares in the last quarter. 5AM Venture Management LLC bought a new position in shares of Pharvaris in the second quarter valued at $27,581,008. Finally, Seven Fleet Capital Management LP increased its holdings in Pharvaris by 144.6% during the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock worth $26,782,000 after buying an additional 457,804 shares during the last quarter.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.